Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

3.865 -0.005 (-0.13%)

Streaming Delayed Price Updated: 11:38 AM EDT, Aug 19, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	806,717
Open	3.900
Bid (Size)	3.860 (900)
Ask (Size)	3.870 (3,100)
Prev. Close	3.870
Today's Range	3.865 - 3.940
52wk Range	2.830 - 15.74
Shares Outstanding	61,758,994
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations

August 18, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal ↗

August 17, 2026

Fulcrum Therapeutics (NASDAQ:FULC) has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in...

Via MarketBeat

Performance

YTD	-64.6%	-64.6%
1 Month	+6.8%	+6.8%
3 Month	-34.6%	-34.6%
6 Month	-63.7%	-63.7%
1 Year	-41.8%	-41.8%

More News

FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

August 17, 2026

From Halper Sadeh LLC

Via Business Wire

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

August 17, 2026

From Fulcrum Therapeutics, Inc.; Slate Medicines

Via GlobeNewswire

Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations

August 13, 2026

Via NewMediaWire

Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Possible Securities Law Violations

August 11, 2026

Via NewMediaWire

Kaplan Fox Notifies Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) of an Investigation Into Potential Securities Law Violations

August 06, 2026

Via NewMediaWire

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding Potential Securities Law Violations

August 04, 2026

Via NewMediaWire

Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) of an Ongoing Investigation Into Potential Securities Law Violations

July 30, 2026

Via NewMediaWire

Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - Investors Encouraged to Contact the Firm

July 28, 2026

Via NewMediaWire

Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - Investors are Encouraged to Contact the Firm

July 23, 2026

Via NewMediaWire

Kaplan Fox Announces an Investigation Into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations

July 21, 2026

Via NewMediaWire

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm to Learn About Their Legal Rights

July 16, 2026

Via NewMediaWire

Kaplan Fox & Kilsheimer LLP Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to a Securities Investigation

July 15, 2026

Via NewMediaWire

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP

June 20, 2026

Via TheNewswire.com

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP

June 20, 2026

Via NewMediaWire

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm

June 19, 2026

Via TheNewswire.com

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm

June 19, 2026

Via NewMediaWire

Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations

June 18, 2026

Via NewMediaWire

Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations

June 18, 2026

Via TheNewswire.com

Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law Violations

June 17, 2026

Via NewMediaWire

Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law Violations

June 17, 2026

Via TheNewswire.com

FULCRUM THERAPEUTICS Investors are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations

June 16, 2026

Via NewMediaWire

FULCRUM THERAPEUTICS Investors are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations

June 16, 2026

Via TheNewswire.com

Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

June 10, 2026

Via NewMediaWire

Frequently Asked Questions

Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?

Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?

Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?

The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market

What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?

The current price of Fulcrum Therapeutics, Inc. - Common Stock is 3.865

When was Fulcrum Therapeutics, Inc. - Common Stock last traded?

The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 08/19/26 11:38 AM ET

What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?

The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 238.70M

How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?

Fulcrum Therapeutics, Inc. - Common Stock has 239M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.